Mortality at 1 year · bullous pemphigoid
It is very uncertain whether methylprednisolone plus azathioprine changes mortality at 1 year compared with methylprednisolone plus dapsone (very low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Proportion of participants achieving control of inflammation (higher number of events is better) · NIIPPU
It is very uncertain whether steroids with or without azathioprine changes proportion of participants achieving control of inflammation (higher… compared with cyclosporine A (very low certainty).
1 finding from 1 review
Change in BCVA (lower logMAR indicate better vision) · NIIPPU
1 finding from 1 review
Proportion of participants achieving a 2‐line improvement in visual acuity (Snellen chart) (higher scores indicate better vision) · NIIPPU
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with confirmed macular edema (lower number of events is better) · NIIPPU
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving steroid‐sparing control (higher number of events is better) · NIIPPU
It is very uncertain whether steroids with or without azathioprine changes proportion of participants achieving steroid‐sparing control (higher… compared with cyclosporine A (very low certainty).
1 finding from 1 review
Proportion of participants experiencing complications or requiring cessation of medication (lower number of events is better) · NIIPPU
It is very uncertain whether steroids with or without azathioprine changes proportion of participants experiencing complications or requiring… compared with cyclosporine A (very low certainty).
1 finding from 1 review
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A plus azathioprine · people undergoing liver transplantation
It is very uncertain whether the intervention changes cyclosporine A plus azathioprine (very low certainty).
1 finding from 1 review
Intervention not reported
Cyclosporine A plus azathioprine plus glucocorticosteroids · people undergoing liver transplantation
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Tacrolimus plus azathioprine · people undergoing liver transplantation
It is very uncertain whether the intervention changes tacrolimus plus azathioprine (very low certainty).
1 finding from 1 review
Death, all cause · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) showed no clear difference in death, all cause compared with azathioprine (AZA) (moderate certainty).
1 finding from 1 review
Graft loss censored for death · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower graft loss, censored for death compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Malignancy · patients with kidney transplant recipients
It is very uncertain whether mycophenolate mofetil (MMF) changes malignancy, any compared with azathioprine (AZA) (very low certainty).
1 finding from 1 review
Acute rejection, steroid resistant/antibody treated As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, steroid resistant/antibody treated As reported in… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Infection, CMV tissue invasive As reported in the articles · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to higher infection, CMV tissue invasive As reported in the articles compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Acute rejection, total Any treated acute rejection, including biopsy‐proven · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) leads to lower acute rejection, total Any treated acute rejection, including… compared with azathioprine (AZA) (high certainty).
1 finding from 1 review
Chronic allograft nephropathy Biopsy required in 2 RCTs, one study with optional biopsy · patients with kidney transplant recipients
Mycophenolate mofetil (MMF) may leads to lower chronic allograft nephropathy Biopsy required in 2 RCTs, one study… compared with azathioprine (AZA) (low certainty).
1 finding from 1 review